Terrie Curran Biography and Net Worth

Terrie Curran is the former President, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene Corporation and has more than 20 years of experience in the biopharmaceutical industry. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA®.

Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Women’s Health at Merck & Co. She currently serves on the Board of Myovant Sciences and previously served on the board of H. Lundbeck A/S.

Ms. Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.

What is Terrie Curran's net worth?: The estimated net worth of Terrie Curran is at least $88,513.47 as of November 11th, 2024. Mr. Curran owns 10,139 shares of Phathom Pharmaceuticals stock worth more than $88,513 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Curran may own. Additionally, Mr. Curran receives a salary of $1,220,000.00 as Insider at Phathom Pharmaceuticals. Learn More about Terrie Curran's net worth.
How old is Terrie Curran?: Mr. Curran is currently 55 years old. There are 4 older executives and no younger executives at Phathom Pharmaceuticals. Learn More on Terrie Curran's age.
What is Terrie Curran's salary?: As the Insider of Phathom Pharmaceuticals, Inc., Mr. Curran earns $1,220,000.00 per year. Learn More on Terrie Curran's salary.
How do I contact Terrie Curran?: The corporate mailing address for Mr. Curran and other Phathom Pharmaceuticals executives is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. Phathom Pharmaceuticals can also be reached via phone at 877-742-8466 and via email at [email protected]. Learn More on Terrie Curran's contact information.
Has Terrie Curran been buying or selling shares of Phathom Pharmaceuticals?: Terrie Curran has not been actively trading shares of Phathom Pharmaceuticals over the course of the past ninety days. Most recently, Terrie Curran sold 33,848 shares of the business's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $11.72, for a transaction totalling $396,698.56. Following the completion of the sale, the insider now directly owns 377,734 shares of the company's stock, valued at $4,427,042.48. Learn More on Terrie Curran's trading history.
Who are Phathom Pharmaceuticals' active insiders?: Phathom Pharmaceuticals' insider roster includes Terrie Curran (Insider), Azmi Nabulsi (COO), and David Socks (Director). Learn More on Phathom Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Phathom Pharmaceuticals?: During the last year, insiders at the sold shares 7 times. They sold a total of 3,779,370 shares worth more than $30,815,661.94. The most recent insider tranaction occured on July, 15th when COO Azmi Nabulsi sold 10,901 shares worth more than $127,759.72. Insiders at Phathom Pharmaceuticals own 24.1% of the company. Learn More about insider trades at Phathom Pharmaceuticals.
Information on this page was last updated on 7/15/2024.

Terrie Curran Insider Trading History at Phathom Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2024	Sell	33,848	$11.72	$396,698.56	377,734
3/22/2024	Sell	16,851	$9.11	$153,512.61	410,784
4/6/2023	Buy	12,919	$7.82	$101,026.58	188,290
3/1/2023	Sell	1,436	$8.54	$12,263.44	175,371
1/20/2023	Sell	5,821	$8.20	$47,732.20	176,807
5/13/2022	Buy	20,500	$7.41	$151,905.00	64,595
3/22/2021	Sell	11,513	$43.32	$498,743.16	11,513

Terrie Curran Buying and Selling Activity at Phathom Pharmaceuticals

Phathom Pharmaceuticals Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Today's Range

Now: $8.73

$8.55

$9.59

50 Day Range

MA: $16.03

$8.73

$19.50

2 Week Range

Now: $8.73

$6.07

$19.71

Volume

1,352,122 shs

Average Volume

1,910,499 shs

Market Capitalization

$596.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Terrie Curran Biography and Net Worth

What is Terrie Curran's net worth?

How old is Terrie Curran?

What is Terrie Curran's salary?

How do I contact Terrie Curran?

Has Terrie Curran been buying or selling shares of Phathom Pharmaceuticals?

Who are Phathom Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Phathom Pharmaceuticals?